Uwell Biopharma, Inc. (TPEX:7902)

Market Cap	8.20B
Revenue (ttm)	35.00K -92.2%
Net Income	-66.20M
EPS	-0.43
Shares Out	200.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	158,855
Average Volume	382,103
Open	41.50
Previous Close	41.60
Day's Range	40.00 - 41.55
52-Week Range	7.80 - 51.50
Beta	n/a
RSI	43.92
Earnings Date	n/a

About Uwell Biopharma

Uwell Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel cancer immunotherapeutic in Taiwan. The company provides chimeric antigen receptor T-cell (CAR-T) therapy platforms, lentiviral vector production, and related services. The company was founded in 2020 and is based in New Taipei City, Taiwan.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2020
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7902

Financial Performance

In 2025, Uwell Biopharma's revenue was 35,000, a decrease of -92.22% compared to the previous year's 450,000. Losses were -66.20 million, 62.0% more than in 2024.